Veraxa Biotech AG (VRXA) FinancialsVRXAFinancialVeraxa Biotech AG

Evaluating the bottom line, Veraxa Biotech AG maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of 5.72%, provide a clear picture of how effectively VRXA converts its operational activities into shareholder value.

In the context of the broader market, VRXA competes directly with industry leaders such as ARMP and NKTX. With a market capitalization of $203.63M, it holds a leading position in the sector. When comparing efficiency, VRXA's gross margin of N/A stands against ARMP's 100.00% and NKTX's N/A. Such benchmarking helps identify whether Veraxa Biotech AG is trading at a premium or discount relative to its financial performance.

Veraxa Biotech AG has reported a net income of 180,498 in Q1 2026, a significant drop from previous quarters, indicating declining profitability. The company's current ratio has fallen to 0.00, highlighting severe liquidity issues, and total equity has turned negative at -14,448,149, suggesting financial distress.